Table 3 Diagnosis (A) and prognostication (B–D) of PCa
From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
PPV | NPV | |
|---|---|---|
A | ||
Benign vs PCa | ||
ProCUrE | 78.10% | 49.10% |
Age-adjusted PSA | 59.80% | 47.40% |
B | ||
GS clinically insignificant vs clinically significant | ||
ProCUrE | 59.40% | 76.40% |
Age-adjusted PSA | 38.20% | 84.20% |
GS6 vs GS ≥ 7 | ||
ProCUrE | 76.00% | 53.70% |
Age-adjusted PSA | 63.90% | 70.00% |
Benign, GS6, GS7(3 + 4) vs GS ≥ 7 (4 + 3) | ||
ProCUrE | 37.5% | 86.8% |
Age-adjusted PSA | 24.5% | 94.7% |
Benign, GS6, GS7 vs GS ≥ 8 | ||
ProCUrE | 31.3% | 94.3% |
Age-adjusted PSA | 16.7% | 100.0% |
C | ||
CAPRA clinically insignificant vs clinically significant | ||
ProCUrE | 59.40% | 73.60% |
Age-adjusted PSA | 42.20% | 86.80% |
CAPRA low risk vs intermediate and high risk | ||
ProCUrE | 76.00% | 48.10% |
Age-adjusted PSA | 70.50% | 75.00% |
D | ||
D’Amico clinically insignificant vs clinically significant | ||
ProCUrE | 59.40% | 68.90% |
Age-adjusted PSA | 43.10% | 76.30% |
D’Amico low risk vs intermediate and high risk | ||
ProCUrE | 76.00% | 38.90% |
Age-adjusted PSA | 72.10% | 55.00% |